Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2017 Annual Meeting | C243 - Assessment of Rapidly Progressive Dementias II: Autoimmune Encephalopathies and Infections Presenting as Rapidly Progressive Dementia

Friday 04/28/17
03:30 PM - 05:30 PM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Seminar
Michael D. Geschwind, MD, PhD, FÂ鶹´«Ã½Ó³»­
Participants should be familiar with the differential diagnosis of infectious and non-prion neurodegenerative disease causes of RPD. They should understand the clinical presentation and be able to evaluate for the more common causes of RPD.
2.00 CME credits
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice
Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider
Case-based, Didactic, Audience Participation
Event Timeline
03:30 PM - 03:35 PM Luncheon Introduction
Michael D. Geschwind, MD, PhD, FÂ鶹´«Ã½Ó³»­
03:35 PM - 04:25 PM Speaker Infectious Causes of Rapidly Progressive Dementia
Allen J. Aksamit, Jr., MD, FÂ鶹´«Ã½Ó³»­
04:25 PM - 05:15 PM Speaker Autoimmune and Antibody-mediated Causes of Rapidly Progressive Dementia
Jeffrey M. Gelfand, MD, MS, FÂ鶹´«Ã½Ó³»­
05:15 PM - 05:30 PM Q&A Questions and Answers
Faculty Disclosures
Jeffrey M. Gelfand, MD, MS, FÂ鶹´«Ã½Ó³»­ Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Michael D. Geschwind, MD, PhD, FÂ鶹´«Ã½Ó³»­ Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Allen J. Aksamit, Jr., MD, FÂ鶹´«Ã½Ó³»­ Dr. Aksamit has nothing to disclose.